Efficacy of carboplatin and paclitaxel therapy in patients with advanced squamous cell carcinoma (SCC) of the anal canal.

539 Background: Development of distant metastases in SCC of the anal canal is not very common after treatment with combined modality. Only widely published data for treatment of metastatic disease is cisplatin and 5-FU. Carboplatin and paclitaxel is commonly used in squamous cancer of the lung but its efficacy in SCC of the anal cancer is unclear. The objective of this study is to determine the tolerability and outcome of patients with SCC of the anal canal treated with carboplatin/paclitaxel at Moffitt Cancer Center. Methods: Retrospective analysis was conducted looking at Moffitt Cancer tumor registry from 1/2007 to 1/2012. Eligible patients were required to have diagnosis of SCC of the anal cancer and received carboplatin/paclitaxel every 3 weeks as part of the treatment. Results: 13 patients fulfilled the criteria. 11 patients were initially diagnosed with early stage (Stage I-III). 11 patients received concurrent chemo radiation (Nigro regimen or cisplatin + 5-FU) and had reoccurrence. 2 patients wer...